Cart
sales@molnova.com
Swertisin
CAS No. 6991-10-2
Swertisin ( —— )
Catalog No. M24716 CAS No. 6991-10-2
Swertisin, a novel herbal biomolecule, shows a strong antihyperglycemic action.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 237 | In Stock |
|
| 10MG | 354 | In Stock |
|
| 25MG | 581 | In Stock |
|
| 50MG | 799 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSwertisin
-
NoteResearch use only, not for human use.
-
Brief DescriptionSwertisin, a novel herbal biomolecule, shows a strong antihyperglycemic action.
-
DescriptionSwertisin, a novel herbal biomolecule, shows a strong antihyperglycemic action. Swertisin is an adenosine A1 receptor antagonist, is known to have antidiabetic, anti-inflammatory and antioxidant effects.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAChR
-
RecptorAdenosine A1?receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6991-10-2
-
Formula Weight446.4
-
Molecular FormulaC22H22O10
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C1C=C(C2=CC=C(O)C=C2)OC3=CC(OC)=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=C13
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.A Small Molecule Swertisin from Enicostemma littorale Differentiates NIH3T3 Cells into Islet-Like Clusters and Restores Normoglycemia upon Transplantation in Diabetic Balb/c Mice.Evid Based Complement Alternat Med. 2013;2013:280392.
molnova catalog
related products
-
DL-trihexyphenidyl h...
One of the centrally acting muscarinic antagonists used for treatment of parkinsonia disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic.
-
Strychnine Sulfate
In smaller doses, strychnine functions as a stimulant and an athletic performance-enhancer.
-
Pirenzepine dihydroc...
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function.
